Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00210600 | Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy | PHASE2 | COMPLETED | 186 | — | — | May 1, 2005 | Aug 1, 2006 | Jun 10, 2011 | - | — |
| Name | Type | Description |
|---|---|---|
| PROCRIT (Epoetin alfa) | DRUG | - |
Inclusion Criteria: * Biopsy confirmed diagnosis of non-myeloid malignancy * Baseline hemoglobin (Hb) value of \>= 11.0 g/dL and \<= 12.0 g/dL * No blood transfusions in the 28 days prior to the start of Treatment Phase * Must be receiving chemotherapy or will begin receiving chemotherapy at start ...